2024 Q3 Form 10-Q Financial Statement
#000162828024033284 Filed on July 29, 2024
Income Statement
| Concept | 2024 Q3 | 2024 Q2 | 2023 Q4 |
|---|---|---|---|
| Revenue | $182.5M | $163.8M | $135.4M |
| YoY Change | 47.69% | 39.15% | 31.39% |
| Cost Of Revenue | $2.867M | $2.524M | $1.877M |
| YoY Change | 74.29% | 60.36% | 26.82% |
| Gross Profit | $179.7M | $161.3M | $133.5M |
| YoY Change | 47.33% | 38.86% | 31.46% |
| Gross Profit Margin | 98.43% | 98.46% | 98.61% |
| Selling, General & Admin | $73.75M | $66.94M | $47.15M |
| YoY Change | 62.93% | 54.65% | 11.41% |
| % of Gross Profit | 41.04% | 41.5% | 35.31% |
| Research & Development | $59.34M | $58.75M | $54.71M |
| YoY Change | 30.36% | 35.74% | 48.85% |
| % of Gross Profit | 33.02% | 36.43% | 40.97% |
| Depreciation & Amortization | $318.0K | $128.0K | $542.0K |
| YoY Change | 218.0% | -31.18% | 196.17% |
| % of Gross Profit | 0.18% | 0.08% | 0.41% |
| Operating Expenses | $133.1M | $125.7M | $101.9M |
| YoY Change | 46.6% | 45.2% | 28.81% |
| Operating Profit | $46.60M | $35.59M | $31.67M |
| YoY Change | 49.46% | 20.31% | 40.76% |
| Interest Expense | $6.345M | $6.004M | $5.140M |
| YoY Change | 22.02% | 79.38% | 189.25% |
| % of Operating Profit | 13.62% | 16.87% | 16.23% |
| Other Income/Expense, Net | $6.345M | $6.004M | |
| YoY Change | 21.83% | 79.38% | |
| Pretax Income | $52.94M | $41.60M | $36.81M |
| YoY Change | 45.51% | 26.32% | 51.63% |
| Income Tax | $5.700M | $6.100M | $5.454M |
| % Of Pretax Income | 10.77% | 14.66% | 14.82% |
| Net Earnings | $47.21M | $35.49M | $31.36M |
| YoY Change | 50.47% | 28.92% | 88.87% |
| Net Earnings / Revenue | 25.86% | 21.67% | 23.16% |
| Basic Earnings Per Share | $0.45 | $0.34 | |
| Diluted Earnings Per Share | $0.41 | $0.32 | $0.28 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 104.5M shares | 104.1M shares | 103.1M shares |
| Diluted Shares Outstanding | 113.7M shares | 111.2M shares |
Balance Sheet
| Concept | 2024 Q3 | 2024 Q2 | 2023 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $380.3M | $473.2M | $368.2M |
| YoY Change | 7.08% | 30.25% | -14.7% |
| Cash & Equivalents | $137.3M | $128.6M | $135.6M |
| Short-Term Investments | $243.0M | $344.6M | $232.7M |
| Other Short-Term Assets | $4.580M | $9.126M | $41.56M |
| YoY Change | -86.61% | -69.44% | 36.61% |
| Inventory | $8.050M | $8.350M | $7.730M |
| Prepaid Expenses | $5.817M | $5.146M | $4.319M |
| Receivables | $59.72M | $53.84M | $41.12M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $467.0M | $560.8M | $458.6M |
| YoY Change | 8.22% | 29.65% | -8.14% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.930M | $1.472M | $195.0K |
| YoY Change | 870.2% | 127.16% | -69.19% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $167.3M | $19.32M | $57.18M |
| YoY Change | 180.72% | 1055.77% | |
| Other Assets | $6.973M | $6.939M | $6.541M |
| YoY Change | 6.62% | -92.41% | 29.32% |
| Total Long-Term Assets | $317.3M | $153.7M | $162.9M |
| YoY Change | 95.25% | 67.01% | 93.5% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $467.0M | $560.8M | $458.6M |
| Total Long-Term Assets | $317.3M | $153.7M | $162.9M |
| Total Assets | $784.3M | $714.6M | $621.5M |
| YoY Change | 32.02% | 36.2% | 6.53% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $18.58M | $19.48M | $17.40M |
| YoY Change | 11.21% | 144.28% | 45.26% |
| Accrued Expenses | $79.46M | $59.25M | $51.63M |
| YoY Change | 14.12% | -9.67% | 67.63% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $126.2M | $100.8M | $104.5M |
| YoY Change | 3.56% | 8.26% | 44.16% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $19.21M | $17.56M | $10.31M |
| YoY Change | 82.91% | 76.47% | 13.3% |
| Total Long-Term Liabilities | $19.21M | $17.56M | $10.31M |
| YoY Change | 82.91% | 76.47% | 13.3% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $126.2M | $100.8M | $104.5M |
| Total Long-Term Liabilities | $19.21M | $17.56M | $10.31M |
| Total Liabilities | $145.4M | $118.3M | $114.8M |
| YoY Change | 9.88% | 14.85% | 40.72% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | $513.0M | $465.8M | $402.5M |
| YoY Change | 38.21% | 37.08% | 35.81% |
| Common Stock | $806.5M | $781.1M | $738.5M |
| YoY Change | 11.62% | 12.26% | 563651.91% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $638.8M | $596.2M | $506.7M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $784.3M | $714.6M | $621.5M |
| YoY Change | 32.02% | 36.2% | 6.53% |
Cashflow Statement
| Concept | 2024 Q3 | 2024 Q2 | 2023 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | $47.21M | $35.49M | $31.36M |
| YoY Change | 50.47% | 28.92% | 88.87% |
| Depreciation, Depletion And Amortization | $318.0K | $128.0K | $542.0K |
| YoY Change | 218.0% | -31.18% | 196.17% |
| Cash From Operating Activities | $73.83M | $41.18M | $5.839M |
| YoY Change | 39.3% | -2.61% | -82.51% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $1.635M | $416.0K | $39.00K |
| YoY Change | 307.84% | 25.81% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$42.40M | -$59.78M | $17.14M |
| YoY Change | -61.31% | 149.13% | -199.62% |
| Cash From Investing Activities | -$44.04M | -$60.19M | $17.11M |
| YoY Change | -59.82% | 149.8% | -199.22% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -21.09M | -2.150M | 777.0K |
| YoY Change | 440.82% | -98.52% | -1373.77% |
| NET CHANGE | |||
| Cash From Operating Activities | 73.83M | 41.18M | 5.839M |
| Cash From Investing Activities | -44.04M | -60.19M | 17.11M |
| Cash From Financing Activities | -21.09M | -2.150M | 777.0K |
| Net Change In Cash | 8.701M | -21.16M | 23.72M |
| YoY Change | -114.38% | -83.41% | 47.47% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | $73.83M | $41.18M | $5.839M |
| Capital Expenditures | $1.635M | $416.0K | $39.00K |
| Free Cash Flow | $72.19M | $40.77M | $5.800M |
| YoY Change | 36.22% | -3.36% | -82.61% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
578000 | usd |
| CY2024Q2 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
5745000 | usd |
| CY2023Q2 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
297000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
27356000 | usd |
| us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
62640000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
62640000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
43173000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
43173000 | usd | |
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
652000 | usd | |
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
2638000 | usd | |
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
2255000 | usd | |
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
0 | usd | |
| cort |
Payments For Repurchase Of Common Stock In Connection With Tender Offer
PaymentsForRepurchaseOfCommonStockInConnectionWithTenderOffer
|
0 | usd | |
| cort |
Payments For Repurchase Of Common Stock In Connection With Tender Offer
PaymentsForRepurchaseOfCommonStockInConnectionWithTenderOffer
|
145428000 | usd | |
| us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
3665000 | usd | |
| us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
3052000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2693000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-145573000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-6963000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
106048000 | usd | |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
135551000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
66329000 | usd |
| CY2024Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
128588000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
172377000 | usd |
| cort |
Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
|
6131000 | usd | |
| CY2024Q1 | cort |
Treasury Stock Value Acquired Excise Tax
TreasuryStockValueAcquiredExciseTax
|
81000 | usd |
| CY2024Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
7574000 | usd |
| CY2024Q2 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
6242000 | usd |
| CY2024Q2 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
3478000 | usd |
| CY2024Q2 | cort |
Treasury Stock Value Acquired Excise Tax
TreasuryStockValueAcquiredExciseTax
|
16000 | usd |
| CY2024Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
13881000 | usd |
| CY2024Q2 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
1314000 | usd |
| CY2024Q2 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-174000 | usd |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
35488000 | usd |
| CY2024Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
596243000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
501842000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
6540000 | usd |
| CY2023Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
6359000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
10966000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
4497000 | usd |
| CY2023Q2 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
4823000 | usd |
| CY2023Q2 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
145428000 | usd |
| CY2023Q2 | cort |
Treasury Stock Value Acquired Excise Tax
TreasuryStockValueAcquiredExciseTax
|
-1316000 | usd |
| cort |
Number Of Series Of Selective Cortisol Modulators
NumberOfSeriesOfSelectiveCortisolModulators
|
4 | series | |
| cort |
Number Of Compounds
NumberOfCompounds
|
1000 | compound | |
| cort |
Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
|
8532000 | usd | |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
506705000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
3485000 | usd |
| CY2024Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
3554000 | usd |
| CY2024Q1 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
476000 | usd |
| CY2024Q1 | cort |
Treasury Stock Value Acquired Excise Tax
TreasuryStockValueAcquiredExciseTax
|
81000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
1283000 | usd |
| CY2024Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-351000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
27762000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
547864000 | usd |
| CY2024Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
7574000 | usd |
| CY2024Q2 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
6242000 | usd |
| CY2024Q2 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
3478000 | usd |
| CY2024Q2 | cort |
Treasury Stock Value Acquired Excise Tax
TreasuryStockValueAcquiredExciseTax
|
16000 | usd |
| CY2024Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
13881000 | usd |
| CY2024Q2 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
1314000 | usd |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
35488000 | usd |
| CY2024Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
596243000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
501842000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
6540000 | usd |
| CY2023Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
6359000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
10966000 | usd |
| CY2023Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
716000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
15879000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
529584000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
4497000 | usd |
| CY2023Q2 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
4823000 | usd |
| CY2023Q2 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
145428000 | usd |
| CY2023Q2 | cort |
Treasury Stock Value Acquired Excise Tax
TreasuryStockValueAcquiredExciseTax
|
-1316000 | usd |
| CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
11374000 | usd |
| CY2023Q2 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
198000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
27528000 | usd |
| CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
421614000 | usd |
| cort |
Number Of Series Of Selective Cortisol Modulators
NumberOfSeriesOfSelectiveCortisolModulators
|
4 | series | |
| cort |
Number Of Compounds
NumberOfCompounds
|
1000 | compound | |
| CY2024Q2 | cort |
Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
|
8451000 | usd |
| CY2023Q4 | cort |
Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
|
8233000 | usd |
| CY2024Q2 | cort |
Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
|
8350000 | usd |
| CY2023Q4 | cort |
Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
|
7741000 | usd |
| CY2024Q2 | cort |
Inventory Current Noncurrent
InventoryCurrentNoncurrent
|
16801000 | usd |
| CY2023Q4 | cort |
Inventory Current Noncurrent
InventoryCurrentNoncurrent
|
15974000 | usd |
| CY2024Q2 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
8451000 | usd |
| CY2023Q4 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
8244000 | usd |
| CY2024Q2 | us-gaap |
Inventory Net
InventoryNet
|
8350000 | usd |
| CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
7730000 | usd |
| CY2024Q2 | cort |
Number Of Manufacturers
NumberOfManufacturers
|
2 | manufacturer |
| CY2024Q2 | cort |
Deferred Clinical Materials Current
DeferredClinicalMaterialsCurrent
|
8328000 | usd |
| CY2023Q4 | cort |
Deferred Clinical Materials Current
DeferredClinicalMaterialsCurrent
|
13496000 | usd |
| CY2024Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
5146000 | usd |
| CY2024Q2 | cort |
Clinical Deposits Current
ClinicalDepositsCurrent
|
2903000 | usd |
| CY2023Q4 | cort |
Clinical Deposits Current
ClinicalDepositsCurrent
|
3865000 | usd |
| CY2024Q2 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
9126000 | usd |
| CY2023Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
5882000 | usd |
| CY2024Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
25503000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
27562000 | usd |
| CY2024Q2 | cort |
Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
|
31651000 | usd |
| CY2023Q4 | cort |
Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
|
18468000 | usd |
| CY2024Q2 | cort |
Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
|
8451000 | usd |
| CY2023Q4 | cort |
Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
|
8233000 | usd |
| CY2024Q2 | cort |
Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
|
8350000 | usd |
| CY2023Q4 | cort |
Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
|
7741000 | usd |
| CY2024Q2 | cort |
Inventory Current Noncurrent
InventoryCurrentNoncurrent
|
16801000 | usd |
| CY2023Q4 | cort |
Inventory Current Noncurrent
InventoryCurrentNoncurrent
|
15974000 | usd |
| CY2024Q2 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
8451000 | usd |
| CY2023Q4 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
8244000 | usd |
| CY2024Q2 | us-gaap |
Inventory Net
InventoryNet
|
8350000 | usd |
| CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
7730000 | usd |
| CY2024Q2 | cort |
Number Of Manufacturers
NumberOfManufacturers
|
2 | manufacturer |
| CY2024Q2 | cort |
Deferred Clinical Materials Current
DeferredClinicalMaterialsCurrent
|
8328000 | usd |
| CY2023Q4 | cort |
Deferred Clinical Materials Current
DeferredClinicalMaterialsCurrent
|
13496000 | usd |
| CY2024Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
5146000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
4319000 | usd |
| CY2024Q2 | cort |
Clinical Deposits Current
ClinicalDepositsCurrent
|
2903000 | usd |
| CY2023Q4 | cort |
Clinical Deposits Current
ClinicalDepositsCurrent
|
3865000 | usd |
| CY2023Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
5882000 | usd |
| CY2024Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
25503000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
27562000 | usd |
| CY2024Q2 | cort |
Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
|
31651000 | usd |
| CY2023Q4 | cort |
Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
|
18468000 | usd |
| CY2024Q2 | cort |
Accrued Compensation Current
AccruedCompensationCurrent
|
17392000 | usd |
| CY2023Q4 | cort |
Accrued Compensation Current
AccruedCompensationCurrent
|
25457000 | usd |
| CY2024Q2 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
3535000 | usd |
| CY2023Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
1771000 | usd |
| CY2024Q2 | cort |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
1376000 | usd |
| CY2023Q4 | cort |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
542000 | usd |
| CY2024Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5296000 | usd |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5390000 | usd |
| CY2024Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
59250000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
51628000 | usd |
| CY2024Q2 | cort |
Deposits For Clinical Trials
DepositsForClinicalTrials
|
5900000 | usd |
| CY2023Q4 | cort |
Deposits For Clinical Trials
DepositsForClinicalTrials
|
6400000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
|
459601000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
|
387016000 | usd |
| CY2024Q2 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
2300000 | usd |
| CY2023Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
1700000 | usd |
| cort |
Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
|
P26M | ||
| cort |
Marketable Securities Short Term Maximum Maturity Period
MarketableSecuritiesShortTermMaximumMaturityPeriod
|
P1Y | ||
| cort |
Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
|
P4M | ||
| CY2024Q2 | cort |
Loss Contingency Accrual Other
LossContingencyAccrualOther
|
0 | usd |
| CY2024Q2 | cort |
Loss Contingency Accrual Provision Other
LossContingencyAccrualProvisionOther
|
0 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P6Y | |
| CY2024Q2 | cort |
Lessee Operating Lease Rentable Area
LesseeOperatingLeaseRentableArea
|
50632 | sqft |
| CY2024Q2 | cort |
Operating Lease Liability Obligated Base Rent
OperatingLeaseLiabilityObligatedBaseRent
|
1500000 | usd |
| us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
1400000 | usd | |
| us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
1200000 | usd | |
| CY2024Q2 | cort |
Accrued Compensation Current
AccruedCompensationCurrent
|
17392000 | usd |
| CY2023Q4 | cort |
Accrued Compensation Current
AccruedCompensationCurrent
|
25457000 | usd |
| CY2024Q2 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
3535000 | usd |
| CY2023Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
1771000 | usd |
| CY2024Q2 | cort |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
1376000 | usd |
| CY2023Q4 | cort |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
542000 | usd |
| CY2024Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5296000 | usd |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5390000 | usd |
| CY2024Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
59250000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
51628000 | usd |
| CY2024Q2 | cort |
Deposits For Clinical Trials
DepositsForClinicalTrials
|
5900000 | usd |
| CY2023Q4 | cort |
Deposits For Clinical Trials
DepositsForClinicalTrials
|
6400000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
|
459601000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
|
387016000 | usd |
| CY2024Q2 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
2300000 | usd |
| CY2023Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
1700000 | usd |
| cort |
Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
|
P26M | ||
| cort |
Marketable Securities Short Term Maximum Maturity Period
MarketableSecuritiesShortTermMaximumMaturityPeriod
|
P1Y | ||
| cort |
Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
|
P4M | ||
| CY2024Q2 | cort |
Loss Contingency Accrual Other
LossContingencyAccrualOther
|
0 | usd |
| CY2024Q2 | cort |
Loss Contingency Accrual Provision Other
LossContingencyAccrualProvisionOther
|
0 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P6Y | |
| CY2024Q2 | cort |
Lessee Operating Lease Rentable Area
LesseeOperatingLeaseRentableArea
|
50632 | sqft |
| CY2024Q2 | cort |
Operating Lease Liability Obligated Base Rent
OperatingLeaseLiabilityObligatedBaseRent
|
1500000 | usd |
| CY2024Q2 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
800000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
600000 | usd |
| us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
1200000 | usd | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1358000 | usd | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1157000 | usd | |
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
5745000 | usd | |
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
297000 | usd | |
| CY2024Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P72M | |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P12M | |
| CY2024Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.085 | |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.080 | |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
0 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1382000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1551000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1598000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1646000 | usd |
| CY2024Q2 | cort |
Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
|
2555000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
8732000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
2083000 | usd |
| CY2024Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
5669000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
8000000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
4100000 | shares |
| CY2024Q2 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
83000 | usd |
| CY2023Q2 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
34000 | usd |
| us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
128000 | usd | |
| us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
126000 | usd | |
| CY2024Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
15290000 | usd |
| CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
11892000 | usd |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
28584000 | usd | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
23125000 | usd | |
| CY2024Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
741000 | usd |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1358000 | usd | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1157000 | usd | |
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
5745000 | usd | |
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
297000 | usd | |
| CY2024Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P72M | |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P12M | |
| CY2024Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.085 | |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.080 | |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
0 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1382000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1551000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1598000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1646000 | usd |
| CY2024Q2 | cort |
Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
|
2555000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
8732000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
2083000 | usd |
| CY2024Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
5669000 | usd |
| cort |
Number Of Stock Option Plans
NumberOfStockOptionPlans
|
1 | plan | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
8000000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
4100000 | shares |
| CY2024Q2 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
83000 | usd |
| CY2023Q2 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
34000 | usd |
| us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
128000 | usd | |
| us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
126000 | usd | |
| CY2024Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
15290000 | usd |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
28584000 | usd | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
23125000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
62640000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
62640000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
43173000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
43173000 | usd | |
| CY2024Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
103118000 | shares |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
101964000 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
102954000 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
104908000 | shares | |
| CY2024Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
8126000 | shares |
| CY2023Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
7626000 | shares |
| us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
7596000 | shares | |
| us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
7584000 | shares | |
| CY2024Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
111244000 | shares |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
109590000 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
110550000 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
112492000 | shares | |
| CY2024Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.34 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.27 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.61 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.41 | ||
| CY2024Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.32 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.25 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.57 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.38 | ||
| CY2024Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
6100000 | usd |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
13300000 | usd | |
| CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
5400000 | usd |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
8000000.0 | usd | |
| CY2024Q2 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
1400000 | usd |
| us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
2000000.0 | usd | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
35120000 | usd |
| CY2024Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
35120000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
27356000 | usd |
| us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
62640000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
62640000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
43173000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
43173000 | usd | |
| CY2024Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
103118000 | shares |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
101964000 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
102954000 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
104908000 | shares | |
| CY2024Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
8126000 | shares |
| CY2023Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
7626000 | shares |
| us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
7596000 | shares | |
| us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
7584000 | shares | |
| CY2024Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
111244000 | shares |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
109590000 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
110550000 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
112492000 | shares | |
| CY2024Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.34 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.27 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.61 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.41 | ||
| CY2024Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.32 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.25 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.57 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.38 | ||
| CY2024Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
6100000 | usd |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
13300000 | usd | |
| CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
5400000 | usd |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
8000000.0 | usd | |
| CY2024Q2 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
1400000 | usd |
| us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
2000000.0 | usd | |
| CY2024Q2 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q2 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q2 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false |
